Compare Novo Nordisk A/S (NVO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Veritone Inc — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: Novo Nordisk A/S is far larger — about 2780.2× Veritone Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Veritone Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Veritone Inc for 12 Days on average.
| NVO | VERI | |
|---|---|---|
Market Cap | $165.31B | $59.46M |
Volume | 11,432,838 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $63.98 | $8.39 |
52-Week Low | $35.29 | $0.59 |
Typical Hold Time | 116 Days | 12 Days |
Enterprise Value | $179.56B | $94.86M |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Veritone (VERI) trades at $0.58, down 16% today, reflecting ongoing investor concerns despite some positive business developments. The stock shows bearish technical signals with moving averages indicating strong selling pressure, while fundamentals reveal significant challenges with a -117.5% net income margin and consistent quarterly losses. Recent news includes a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are offset by ongoing securities litigation investigations.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests substantial upside potential with a $3.75 price target. Key risks include the company's inability to achieve profitability, competitive pressures in AI solutions, and legal uncertainties. The stock presents high-risk speculation with potential for recovery if cost reductions and new partnerships drive meaningful revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
